TY - JOUR
T1 - The relationship of circulating fibroblast growth factor 21 levels with incident atrial fibrillation
T2 - The Multi-Ethnic Study of Atherosclerosis
AU - Hui, Tsz Him
AU - McClelland, Robyn L.
AU - Allison, Matthew A.
AU - Rodriguez, Carlos J.
AU - Kronmal, Richard A.
AU - Heckbert, Susan R.
AU - Michos, Erin D.
AU - Barter, Philip J.
AU - Rye, Kerry Anne
AU - Ong, Kwok Leung
N1 - Funding Information:
The FGF21 level measurement was supported by the NSW CVRN Research Development Project Grant ( 100715 ) from the National Heart Foundation of Australia to Dr. Kwok Leung Ong. Kwok Leung Ong was supported by the Vice-Chancellor's Postdoctoral Fellowship from the University of New South Wales ( RG134592 ) and the Australian National Health and Medical Research Council Career Development Fellowship ( 1122854 ). The MESA study was supported by contracts HHSN268201500003I , N01-HC-95159 , N01-HC-95160 , N01-HC-95161 , N01-HC-95162 , N01-HC-95163 , N01-HC-95164 , N01-HC-95165 , N01-HC-95166 , N01-HC-95167 , N01-HC-95168 , N01-HC-95169 and R01-HL-127659 from the National Heart, Lung, and Blood Institute , by grants UL1-TR-000040 , UL1-TR-001079 , and UL1-TR-001420 from National Center for Advancing Translational Sciences .
Publisher Copyright:
© 2017 Elsevier B.V.
PY - 2018/2/1
Y1 - 2018/2/1
N2 - Background and aims: Elevated circulating levels of fibroblast growth factor 21 (FGF21) are associated with multiple cardiovascular disease (CVD) risk factors and incident events. Previous small cross-sectional studies, mainly in Chinese populations, have suggested FGF21 may play a role in the development of atrial fibrillation (AF). We therefore investigated the relationship of FGF21 levels with incident AF in participants free of clinically apparent CVD at baseline in a large, multi-ethnic cohort. Methods: A total of 5729 participants of four major ethnic groups (Caucasian, African American, Hispanic American, and Chinese American) from the Multi-Ethnic Study of Atherosclerosis (MESA), who were free of AF and had plasma FGF21 levels measured by ELISA at the baseline exam, were included in the analysis. Participants were followed up for incident AF over a median period of 12.9 years. Cox proportional hazards regression analysis was used. Results: Among the 5729 participants, 778 participants developed incident AF. Participants with incident AF had significantly higher baseline FGF21 levels than those without incident AF (median = 166.0 and 142.8 pg/mL, p < 0.001). After adjusting for possible confounders, including demographic, socioeconomic and lifestyle factors, traditional CVD risk factors and circulating inflammatory markers, higher baseline FGF21 levels did not predict incident AF over the follow up period. There was no effect modification by sex or ethnicity. Conclusions: Baseline FGF21 levels were not associated with the development of AF in an ethnically diverse population followed long-term. Our findings do not support an important role of FGF21 in AF development.
AB - Background and aims: Elevated circulating levels of fibroblast growth factor 21 (FGF21) are associated with multiple cardiovascular disease (CVD) risk factors and incident events. Previous small cross-sectional studies, mainly in Chinese populations, have suggested FGF21 may play a role in the development of atrial fibrillation (AF). We therefore investigated the relationship of FGF21 levels with incident AF in participants free of clinically apparent CVD at baseline in a large, multi-ethnic cohort. Methods: A total of 5729 participants of four major ethnic groups (Caucasian, African American, Hispanic American, and Chinese American) from the Multi-Ethnic Study of Atherosclerosis (MESA), who were free of AF and had plasma FGF21 levels measured by ELISA at the baseline exam, were included in the analysis. Participants were followed up for incident AF over a median period of 12.9 years. Cox proportional hazards regression analysis was used. Results: Among the 5729 participants, 778 participants developed incident AF. Participants with incident AF had significantly higher baseline FGF21 levels than those without incident AF (median = 166.0 and 142.8 pg/mL, p < 0.001). After adjusting for possible confounders, including demographic, socioeconomic and lifestyle factors, traditional CVD risk factors and circulating inflammatory markers, higher baseline FGF21 levels did not predict incident AF over the follow up period. There was no effect modification by sex or ethnicity. Conclusions: Baseline FGF21 levels were not associated with the development of AF in an ethnically diverse population followed long-term. Our findings do not support an important role of FGF21 in AF development.
KW - Atrial fibrillation
KW - Cardiovascular disease
KW - Fibroblast growth factor 21
KW - Multi-ethnic study of atherosclerosis
UR - http://www.scopus.com/inward/record.url?scp=85042942190&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85042942190&partnerID=8YFLogxK
U2 - 10.1016/j.atherosclerosis.2017.12.026
DO - 10.1016/j.atherosclerosis.2017.12.026
M3 - Article
C2 - 29351855
AN - SCOPUS:85042942190
SN - 0021-9150
VL - 269
SP - 86
EP - 91
JO - Atherosclerosis
JF - Atherosclerosis
ER -